Mapping-Guided Ablation for Persistent Atrial Fibrillation (MAP-AF): A Multicenter, Single-Blind, Randomized Controlled Trial

Author:

Takahashi Yoshihide12ORCID,Kobori Atsushi3ORCID,Hiroshima Kenichi4,Sakamoto Yuichiro5,Kimura Masaomi6ORCID,Inaba Osamu7ORCID,Tanimoto Kojiro8ORCID,Hanazawa Ryoichi9ORCID,Hirakawa Akihiro9ORCID,Goya Masahiko1ORCID,Sasano Tetsuo1ORCID

Affiliation:

1. Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences (Y.T., M.G., T.S.).

2. Department of Cardiology, Shin-Yurigaoka General Hospital, Kawasaki (Y.T.).

3. Department of Cardiology, Kobe City Medical Center General Hospital, Japan (A.K.).

4. Department of Cardiology, Kokura Memorial Hospital, Japan (K.H.).

5. Department of Cardiovascular Medicine, Toyohashi Heart Center, Japan (Y.S.).

6. Department of Cardiology, Hirosaki University Graduate School of Medicine, Japan (M.K.).

7. Department of Cardiology, Japanese Red Cross Saitama Hospital, Japan (O.I.).

8. Department of Cardiology, Tokyo Medical Center, Japan (K.T.).

9. Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan (R.H., A.H.).

Abstract

BACKGROUND: The clinical outcome of pulmonary vein isolation (PVI) for persistent atrial fibrillation (AF) is suboptimal. Mapping studies have demonstrated atrial sites outside of the pulmonary veins displaying focal activation patterns during AF. We sought to determine whether adding catheter ablation of focal activation sites to PVI improves clinical outcomes of catheter ablation for persistent AF. METHODS: In this multicenter, randomized, single-blinded trial, we assigned patients with persistent AF to either PVI alone or to mapping-guided ablation of focal activation sites in addition to PVI in a 1:1 ratio. In the mapping-guided group, both atria were mapped after PVI using a Pentaray catheter (Biosense-Webster) and focal activation sites identified by CARTOFINDER (Biosense-Webster) were ablated. The primary end point was freedom from AF or atrial tachycardia without antiarrhythmic drugs beyond a 90-day blanking period. RESULTS: A total of 98 patients were assigned to the mapping-guided group and 102 to the PVI alone group. In the mapping-guided group, focal activation sites were identified at 2.6±0.3 and 2.5±0.2 sites per patient in the left and right atrium, respectively. Patients were followed up for 768.5 (interquartile range, 723.75–915.75) and 755.5 days (interquartile range, 728.5–913.75) in the mapping-guided ablation and the PVI alone groups, respectively. Freedom from AF/atrial tachycardia without antiarrhythmic drugs at 2-year follow-up was 66.8% and 75.2% in the mapping-guided ablation and the PVI alone groups, respectively (hazard ratio, 1.26 [95% CI, 0.76–2.10]; P =0.37). Adverse events occurred in 3 patients (3.0%) and none (0%) in the mapping-guided ablation and the PVI alone groups, respectively ( P =0.12). CONCLUSIONS: In patients with persistent AF, the addition of mapping-guided ablation of focal activation sites to PVI did not improve clinical outcomes compared with PVI alone. REGISTRATION: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr/index.cgi?function=02 ; Unique identifier: UMIN000037569.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3